Jazz Pharmaceuticals plc (JAZZ) News
Follow Jazz Pharmaceuticals plc (JAZZ) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 44 public stories across 24 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Jazz Pharmaceuticals Raises 2026 Revenue Outlook to $4.775B-$4.85B
The company reported third-quarter Xywav sales up 12% year over year and Zepzelca sales up 32%, partly offset by declines in Epidiolex and Xyrem. Gross-margin guidance remains 89%-90%, with a GAAP tax rate forecast of 20
EARNINGS | Nov 09, 2026, 06:02 PM UTC
L
Form SCHEDULE 13G/A Jazz Pharmaceuticals Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:21 PM UTC
M
Jazz Pharmaceuticals reports fiscal Q3 profit
Jazz Pharmaceuticals reported fiscal 2026 third-quarter profit attributable to shareholders, up 100.45% year over year.
EQUITY | Nov 03, 2026, 05:33 AM UTC
M
Jazz Pharmaceuticals eleva previsión de ingresos para 2026
EARNINGS | Nov 02, 2026, 09:40 PM UTC
M
Jazz Pharmaceuticals raises 2026 revenue guidance to $4.78 billion-$4.85 billion
EARNINGS | Nov 02, 2026, 09:40 PM UTC
M
Jazz Pharmaceuticals Reports Third-Quarter Revenue of $1.24 Billion
EQUITY | Nov 02, 2026, 09:33 PM UTC
M
Jazz Pharmaceuticals reports third-quarter loss per share of $7.48
EQUITY | Nov 02, 2026, 09:18 PM UTC
M
Jazz Pharmaceuticals Expects $755 Million Charge to Impact Q3 Earnings
EQUITY | Oct 26, 2026, 09:37 PM UTC
M
Jazz Pharmaceuticals Q3'26 Results Preview
Jazz Pharmaceuticals is scheduled to report Q3'26 results on November 2 after the market closes. Revenue and EPS estimates were provided.
EQUITY | Oct 26, 2026, 11:00 AM UTC
M
Jazz Pharmaceuticals to report third-quarter results November 2, 2026
EQUITY | Oct 19, 2026, 08:16 PM UTC
L
Jazz Pharmaceuticals Initiated at Buy by Citigroup
Ratings actions from Benzinga
NEWS | Sep 30, 2026, 12:04 PM UTC
L
Weekly Recap: Term Loan B restructured and $337 target for JAZZ
Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) restructured its Term Loan B—issuing Tranche B-3 due May 5, 2033, repriced to SOFR+1.75% with a 0.50% floor and 0.25% quarterly amortization while borrowing ~$273
NEWS | Sep 28, 2026, 11:02 AM UTC
L
Jazz Pharmaceuticals Price Target Announced at $337.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 01:15 PM UTC
L
Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
Jazz Pharmaceuticals PLC NASDAQ:JAZZ
NEWS | Sep 23, 2026, 09:23 PM UTC
L
Jazz Pharmaceuticals Extends And Reprices $1.895 Billion Term Loan B To 2033
Jazz Pharmaceuticals entered into Amendment No. 4 to its Credit Agreement to extend and reprice its U.S. dollar term loan, converting Tranche B-2 into a new $1.895 billion Tranche B-3. The maturity moves to May 5, 2033,
NEWS | Sep 23, 2026, 08:50 PM UTC
L
Jazz Pharmaceuticals completes $820M acquisition of Actio Biosciences, adds ABS-1230 epilepsy candidate
Jazz Pharmaceuticals completed the $820 million acquisition of Actio Biosciences, gaining ABS-1230, a clinical-stage KCNT1-related epilepsy therapy candidate.Key Highlights:Original SEC Filing: Jazz Pharmaceuticals plc [
MNA | Sep 15, 2026, 01:14 PM UTC
L
Jazz Pharmaceuticals Completes Acquisition Of Actio Biosciences >JAZZ
Jazz Pharmaceuticals Completes Acquisition Of Actio Biosciences >JAZZ
MNA | Sep 15, 2026, 01:00 PM UTC
L
Barclays maintains Jazz Pharmaceuticals at Overweight
Barclays maintained its Overweight rating on Jazz Pharmaceuticals, according to Benzinga’s ratings-actions roundup. No price target change or additional details were provided in the feed.
EQUITY | Sep 10, 2026, 01:22 PM UTC
L
JAZZ says strong execution and pipeline innovation drove robust growth
The company attributes Q2 revenue growth to strong execution across its key brands, resilient performance from Xywav, and successful launches of Rylaze and ZEPZELCA. It also cites Ziihera’s expected transformative GEA la
EARNINGS | Sep 09, 2026, 07:10 PM UTC
L
JAZZ boosts outlook as Q2 revenue and pipeline expansion support growth
JAZZ reported record Q2 revenue and broad portfolio growth, citing resilient brands and successful new launches. Ziihera peak sales outlook increased to $3–$5 billion, with expansion into multiple cancer indications.
EARNINGS | Sep 09, 2026, 06:29 PM UTC
L
JAZZ - Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
JAZZ - Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 08:15 PM UTC
L
Jazz Pharmaceuticals raises $1.25 billion via 2032 exchangeable notes
Jazz Pharmaceuticals raised $1.25 billion through 1.875% exchangeable notes due 2032.
EQUITY | Aug 31, 2026, 09:44 PM UTC
L
Jazz Pharmaceuticals agrees $225.0M share repurchase via private transactions
Jazz Pharmaceuticals also agreed to a concurrent $225.0M share repurchase from note purchasers in privately negotiated transactions.
EQUITY | Aug 27, 2026, 04:50 AM UTC
L
Jazz Pharmaceuticals expects proceeds for general purposes
Jazz Pharmaceuticals expects to use proceeds for general purposes.
EQUITY | Aug 27, 2026, 04:46 AM UTC
L
Jazz Pharmaceuticals expects net proceeds of $1.08B, $1.23B if option exercised
Jazz Pharmaceuticals expects net proceeds of $1.08B from its offering, $1.23B if the option is exercised in full.
EQUITY | Aug 27, 2026, 04:43 AM UTC
L
Jazz Pharmaceuticals grants initial purchasers right to buy $150.0M more notes
Jazz Pharmaceuticals granted initial purchasers the right to purchase additional $150.0M of notes.
EQUITY | Aug 27, 2026, 04:41 AM UTC
L
Jazz Pharmaceuticals expects note sale to close Aug. 31
Jazz Pharmaceuticals expects its note sale to close on Aug. 31.
EQUITY | Aug 27, 2026, 04:39 AM UTC
L
Jazz Pharmaceuticals upsizes note offering announced previously
Jazz Pharmaceuticals upsized its note offering from $1.0B previously announced.
EQUITY | Aug 27, 2026, 04:39 AM UTC
M
Jazz Pharmaceuticals prices upsized $1.1B notes offer
Jazz Pharmaceuticals priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032. It will repurchase ordinary shares concurrently.
EQUITY | Aug 27, 2026, 04:37 AM UTC
L
Deutsche Bank reiterates Buy on Jazz Pharmaceuticals
Deutsche Bank maintained its Buy rating on Jazz Pharmaceuticals, according to TradingView News.
EQUITY | Aug 26, 2026, 06:09 PM UTC
L
Jazz Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
Jazz Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
EQUITY | Aug 26, 2026, 04:34 PM UTC
M
Jazz Pharmaceuticals announces private offering of 2032 exchangeable notes
Jazz Pharmaceuticals said it is offering $1.0 billion of exchangeable senior notes due 2032 via a private offering and will repurchase ordinary shares concurrently.
EQUITY | Aug 26, 2026, 11:01 AM UTC
L
AbCellera rises as FDA approves Jazz Ziihera regimens
AbCellera Biologics shares trade higher on Tuesday as investors react to FDA approval of Jazz Pharmaceuticals’ two Ziihera-containing first-line regimens, with no company-specific catalyst supplied.
GEOPOLITICS | Aug 25, 2026, 06:38 PM UTC
H
JAZZ FDA approves Ziihera® in first-line HER2+ advanced GE adenocarcinoma
Jazz Pharmaceuticals says the U.S. FDA approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus chemotherapy in first-line HER2+ advanced gastroesophageal adenocarcinoma.
EQUITY | Aug 25, 2026, 02:02 PM UTC
M
Jazz Pharmaceuticals Price Target 300
Jefferies sets Jazz Pharmaceuticals price target at 300
EQUITY | Aug 12, 2026, 09:17 AM UTC
L
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) on Monday reported better-than-expected second-quarter sales results and raised its FY26 sales guidance above estimates. Jazz Pharmaceuticals reported quarterly earnings of $5.71
EARNINGS | Aug 04, 2026, 11:54 AM UTC
L
Jazz Pharmaceuticals Raises FY2026 Sales Guidance from $4.250B-$4.500B to $4.600B-$4.750B vs $4.517B Est
Jazz Pharmaceuticals (NASDAQ: JAZZ ) raises FY2026 sales outlook from $4.250 billion-$4.500 billion to $4.600 billion-$4.750 billion vs $4.517 billion estimate.
EARNINGS | Aug 03, 2026, 08:11 PM UTC
L
Jazz Reports Q2 Adj. EPS $2.78
Jazz Q2 earnings beat estimates
EARNINGS | Aug 03, 2026, 08:08 PM UTC
L
JAZZ JAZZ - Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
JAZZ JAZZ - Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
EARNINGS | Aug 03, 2026, 08:05 PM UTC
H
US Stocks: Implied EPS Movers
Stocks with large implied EPS moves tonight
EARNINGS | Aug 03, 2026, 06:15 PM UTC
L
Apple upgraded, Brinker initiated: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: HSBC upgraded Apple (AAPL) to Buy
EQUITY | Jul 17, 2026, 01:43 PM UTC
H
Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says
() -- Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Frida
EARNINGS | Jul 10, 2026, 05:01 PM UTC
H
Jazz Pharmaceuticals price target lowered to $254 from $256 at Truist
Truist analyst Gregory Renza lowered the firm's price target on Jazz Pharmaceuticals to $254 from $256 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2
EQUITY | Jul 07, 2026, 01:15 PM UTC
L
Jazz Pharmaceuticals Insider Sold Shares Worth $1,442,820, According to a Recent SEC Filing
() -- Bruce C Cozadd, Director, on July 01, 2026, sold 6,000 shares in Jazz Pharmaceuticals (JAZZ) for $1,442,820. Following the Form 4 filing with the SEC, Cozadd has control over a total of 366,682 ordinary shares of t
REGULATION | Jul 07, 2026, 08:02 AM UTC